@FiercePharma: Has pharma outgrown the scientist CEO? Report | Follow @FiercePharma
> Within hours of being elected, KV Pharmaceutical's new board members ousted interim President and Chief Executive David Van Vliet and installed Gregory Divis in his place. Release | Report
> A deputy chief of China's food and drug regulator has been sacked and is being investigated for disciplinary violations, flagging another possible corruption scandal for the watchdog. Report
> To check the import of unauthorised active pharmaceutical ingredients from China, India may send drug inspectors to examine certain bulk drug production units there. Report
> Dr. Reddy's Laboratories saw its Mumbai shares fall the most in more than four months after a court in the U.S. blocked sales of its version of allergy medication Allegra. Report
> Abbott Vascular, a division of Abbott Laboratories, laid off 120 workers from its California operations. Report
> Gilead Sciences (GILD.O) said it may take legal action against Lupin (LUPN.BO) after the Indian firm applied for FDA approval to manufacture a generic version of its angina drug, Ranexa. Report
> Cadila Pharmaceuticals and Novavax have completed construction of their joint venture vaccine manufacturing plant in Dholka, India. Report
Biotech News
@FierceBiotech: Big Pharma coalition will pool data on failed Alzheimer's drugs. Report | Follow @FierceBiotech
@JohnCFierce: Ain't it cool science: Plastic antibodies used to "cure "mice of bee venom. Report | Follow @JohnCFierce
> Analysis: Fewer approvals may prove R&D is getting tougher. Article
> BioScale banks $25M to back protein analytics tech. Report
> Agile raises $45M for contraceptive patch trials. News
> HGS's hep C drug Zalbin hits an FDA hurdle. Item
Biotech IT News
> Merck's cancer network pushes collaboration. Interview
> Nextrials, Formedix integrate platforms. Report
> Perceptive, XClinical debut study-design automation tools. Article
> Big pharmas to share Alzheimer's drug data. Article
And Finally... A plan by Navistar International to drop some retirees' prescription benefits has run into union opposition, turning into a skirmish that is likely to be replayed at other U.S. companies amid federal health-care changes. Report